newsfilter
← Latest News
Business Wire·

FDA Grants Priority Review of ImmunoGen's Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer

Priority Review Granted with PDUFA Date of April 5, 2024 ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food